Phase II evaluation of menogaril in patients with advanced hypernephroma

Harry J. Long; Mark D. Hauge; Terry M. Therneau; Jan C. Buckner; Stephen Frytak; Richard G. Hahn

doi:10.1007/BF00176980

Phase II evaluation of menogaril in patients with advanced hypernephroma

Harry J. Long, Mark D. Hauge, Terry M. Therneau, Jan C. Buckner, Stephen Frytak, Richard G. Hahn

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m² by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

Original language	English (US)
Pages (from-to)	261-262
Number of pages	2
Journal	Investigational New Drugs
Volume	9
Issue number	3
DOIs	https://doi.org/10.1007/BF00176980
State	Published - Aug 1991

Keywords

hypernephroma
menogaril
phase II
renal cell carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00176980

Cite this

@article{2466785cbd4f4919b5e892c42d71fc10,

title = "Phase II evaluation of menogaril in patients with advanced hypernephroma",

abstract = "Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.",

keywords = "hypernephroma, menogaril, phase II, renal cell carcinoma",

author = "Long, {Harry J.} and Hauge, {Mark D.} and Therneau, {Terry M.} and Buckner, {Jan C.} and Stephen Frytak and Hahn, {Richard G.}",

year = "1991",

month = aug,

doi = "10.1007/BF00176980",

language = "English (US)",

volume = "9",

pages = "261--262",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II evaluation of menogaril in patients with advanced hypernephroma

AU - Long, Harry J.

AU - Hauge, Mark D.

AU - Therneau, Terry M.

AU - Buckner, Jan C.

AU - Frytak, Stephen

AU - Hahn, Richard G.

PY - 1991/8

Y1 - 1991/8

N2 - Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

AB - Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.

KW - hypernephroma

KW - menogaril

KW - phase II

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0025726665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025726665&partnerID=8YFLogxK

U2 - 10.1007/BF00176980

DO - 10.1007/BF00176980

M3 - Article

C2 - 1838363

AN - SCOPUS:0025726665

SN - 0167-6997

VL - 9

SP - 261

EP - 262

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II evaluation of menogaril in patients with advanced hypernephroma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this